What is Starr Life Sciences?
Starr Life Sciences operates as a premier developer of sophisticated monitoring solutions tailored for small animal research. The company's product portfolio, which includes the industry-standard MouseOx Plus pulse oximetry system and the VitalView E-Mitter telemetry platform, provides researchers with granular data on physiological health and behavioral patterns. These tools are essential for laboratories conducting longitudinal studies, offering clinically validated accuracy that is frequently cited in peer-reviewed scientific literature. By bridging the gap between complex biological data and actionable research insights, Starr Life Sciences serves as a foundational partner for academic and commercial institutions focused on advancing life science discovery.
How much funding has Starr Life Sciences raised?
Starr Life Sciences has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Starr Life Sciences
PPP
Public-Private Partnership
What's next for Starr Life Sciences?
With the successful acquisition of this late-stage financing, Starr Life Sciences is well-positioned to accelerate its product development roadmap and expand its global distribution footprint. The strategic focus will likely shift toward integrating advanced data analytics into their existing telemetry hardware, thereby enhancing the utility of their monitoring systems for high-throughput screening environments. As the demand for precise, non-invasive small animal monitoring continues to rise, the company is poised to leverage its established market authority to capture additional share in the preclinical research market, potentially exploring new therapeutic areas where their diagnostic precision can provide a competitive advantage in drug development and physiological modeling.
See full Starr Life Sciences company page
